Inbeeo

🔬 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗔𝗠𝗥 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗜𝗻𝗯𝗲𝗲𝗼’𝘀 𝗜𝗦𝗣𝗢𝗥 𝟮𝟬𝟮𝟰 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻🌍 🚨 Thank you to everyone who stopped by our Inbeeo poster at ISPOR—The Professional Society for Health Economics and Outcomes Research on 𝗿𝗲𝗶𝗺𝗯𝘂𝗿𝘀𝗲𝗺𝗲𝗻𝘁 𝗶𝗻𝗰𝗲𝗻𝘁𝗶𝘃𝗲𝘀 𝗳𝗼𝗿 𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗘𝗨 𝗰𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀, presented by our consultant Tania Savant! 💡 The discussions sparked by our poster highlighted some fascinating trends and challenges in tackling antimicrobial resistance (AMR). Here are a few key takeaways: ➡️ 𝗖𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 𝗮𝗿𝗲 𝘀𝘁𝗮𝗿𝘁𝗶𝗻𝗴 𝘁𝗼 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝘇𝗲 𝗔𝗠𝗥: UK, Sweden, Germany and France are great examples, with P&R incentives in place for antibiotics addressing AMR. ➡️ 𝗜𝘁𝗮𝗹𝘆 𝗶𝘀 𝘁𝗮𝗸𝗶𝗻𝗴 𝗶𝘁 𝗮 𝘀𝘁𝗲𝗽 𝗳𝘂𝗿𝘁𝗵𝗲𝗿, providing significant funding to foster research and innovation in AMR. This example underscores the critical role of government support—check out this inspiring initiative from the Italian government contributing $21M to research! https://lnkd.in/epuQctuT. ➡️ 𝗣𝗼𝗹𝗶𝗰𝗶𝗲𝘀 𝗮𝗿𝗲 𝗮 𝗰𝗿𝘂𝗰𝗶𝗮𝗹 𝘀𝘁𝗲𝗽 𝗳𝗼𝗿𝘄𝗮𝗿𝗱, 𝗯𝘂𝘁 𝘁𝗵𝗲𝘆 𝗮𝗹𝗼𝗻𝗲 𝗮𝗿𝗲 𝗻𝗼𝘁 𝘀𝘂𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁: Manufacturers advocate for stronger, aligned incentives to ensure sustainable antibiotic innovation and market access. The gap between policy ambition and practical implementation remains a challenge. 🌍 Tackling AMR requires 𝗮 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗲𝗳𝗳𝗼𝗿𝘁 across policymakers, healthcare systems, and manufacturers. Let’s continue to discuss how we can collectively create sustainable solutions that benefit patients and safeguard public health. Thank you to everyone who joined us and engaged in insightful discussions! If you couldn’t attend but would like to learn more, feel free to reach out—we’d love to connect and share our in-depth findings! Tania Savant Enzo Straccia Herve Lilliu! #AMR #ISPOR2024 #MarketAccess #Inbeeo #Reimbursement #Antibiotics #HealthPolicy  

🇸🇪𝗔𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗦𝘄𝗲𝗱𝗲𝗻: 𝗧𝗵𝗲 𝗥𝗼𝗹𝗲 𝗼𝗳 𝗠𝗮𝗻𝗮𝗴𝗲𝗱 𝗘𝗻𝘁𝗿𝘆 𝗔𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁𝘀 (𝗠𝗘𝗔𝘀)🇸🇪 How are MEAs reshaping access to novel therapies in Sweden? In Sweden, MEAs are now central tools for ensuring access to innovative therapies while managing healthcare costs. Currently, 𝗼𝘃𝗲𝗿 𝗵𝗮𝗹𝗳 𝗼𝗳 𝗻𝗲𝘄 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘀𝗮𝗹𝗲𝘀 𝗮𝗿𝗲 𝗰𝗼𝘃𝗲𝗿𝗲𝗱 𝗯𝘆 𝗠𝗘𝗔𝘀, which often use confidential rebates and outcome-based payments to balance affordability and value. 🔍 𝗛𝗼𝘄 𝗠𝗘𝗔𝘀 𝗪𝗼𝗿𝗸  MEAs complement Sweden’s value-based pricing system for outpatient drugs, addressing uncertainties around costs and patient volumes while allowing flexibility for local needs through three key players: • 𝗧𝗟𝗩 (𝗗𝗲𝗻𝘁𝗮𝗹 𝗮𝗻𝗱 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗔𝗴𝗲𝗻𝗰𝘆): Sets national standards for cost-effectiveness and access. • 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗔𝘂𝘁𝗵𝗼𝗿𝗶𝘁𝗶𝗲𝘀: Negotiate agreements to align with local budgets and healthcare priorities. • 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀: Collaborate to support both access and cost containment. 🚀 𝗙𝘂𝘁𝘂𝗿𝗲 𝗧𝗿𝗲𝗻𝗱𝘀 𝗮𝗻𝗱 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀  With drug costs rising around 5% annually, MEAs are increasingly critical for maintaining sustainable access to high-cost therapies. TLV is exploring new MEA models, including outcome-based payments, to better support advanced therapies. 📊 𝗣𝗼𝗹𝗶𝗰𝘆 𝗮𝗻𝗱 𝗘𝗾𝘂𝗶𝘁𝘆  𝗘𝗾𝘂𝗮𝗹 𝗮𝗰𝗰𝗲𝘀𝘀 is a cornerstone of Sweden’s healthcare system and remains high on the political agenda. While MEAs can accelerate access to innovative therapies, Sweden’s decentralized healthcare model—where regional authorities negotiate MEAs—can lead to variations in access across regions. The government is considering steps to centralize certain aspects of medicine access to ensure equitable access across all regions. 📈 𝗪𝗵𝗮𝘁 𝗧𝗵𝗶𝘀 𝗠𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝗣𝗵𝗮𝗿𝗺𝗮 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀  For companies entering the Swedish market, understanding both TLV’s value-based pricing approach and the nuances of regional MEA negotiations is essential. Monitoring policy developments toward national coordination will also be crucial. Balancing cost-effectiveness with equitable access will continue to be fundamental—especially for high-cost, innovative therapies. Interested in navigating MEAs and staying ahead of policy changes in Sweden? 📩 Contact Charlotte Langbo and Elisabetta Cesari to discuss how we can help you navigate these complexities and optimize access to your innovative products in Sweden! Contribution by Elisabetta Cesari, our Senior Associate at Inbeeo! #ManagedEntryAgreements #MarketAccess #InnovativeTherapies #Sweden #EquitableAccess 

🌍 𝗜𝗦𝗣𝗢𝗥 𝗘𝗨 𝟮𝟬𝟮𝟰 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: 𝗦𝘁𝗿𝗶𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗥𝗶𝗴𝗵𝘁 𝗕𝗮𝗹𝗮𝗻𝗰𝗲 𝗕𝗲𝘁𝘄𝗲𝗲𝗻 𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗮𝗻𝗱 𝗙𝗮𝗰𝗶𝗹𝗶𝘁𝗮𝘁𝗶𝗻𝗴 𝗨𝗽𝘁𝗮𝗸𝗲 ⚖️💊 Thank you to everyone who attended the Inbeeo podium presentation on Biosimilars delivered by our Senior Consultant Vishal Yadav at ISPOR EU 2024! We are excited to share some key takeaways from our discussion on biosimilars: 🔑 𝗕𝗮𝗹𝗮𝗻𝗰𝗶𝗻𝗴 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗲𝗱 𝗽𝗿𝗶𝗰𝗶𝗻𝗴 𝗽𝗼𝗹𝗶𝗰𝗶𝗲𝘀 𝗮𝗻𝗱 𝘂𝗽𝘁𝗮𝗸𝗲 is crucial for a healthy biosimilar market. 💡 𝗟𝗼𝘄𝗲𝗿 𝗰𝗼𝘀𝘁𝘀 𝗱𝗼𝗻’𝘁 𝗮𝗹𝘄𝗮𝘆𝘀 𝗺𝗲𝗮𝗻 𝗵𝗶𝗴𝗵𝗲𝗿 𝘂𝗽𝘁𝗮𝗸𝗲. For instance, France has stringent price-setting criteria but the lowest biosimilar uptake among the five markets analysed. ✅In contrast, the 𝗨𝗞 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝘀 𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗽𝗿𝗶𝗰𝗶𝗻𝗴 𝘄𝗵𝗶𝗹𝗲 𝗺𝗮𝗶𝗻𝘁𝗮𝗶𝗻𝗶𝗻𝗴 𝗴𝗿𝗲𝗮𝘁𝗲𝗿 𝗺𝗮𝗿𝗸𝗲𝘁 𝗽𝗲𝗻𝗲𝘁𝗿𝗮𝘁𝗶𝗼𝗻. This success is driven by centralized national-level tenders and NHS switching policies. As biosimilar markets mature, pricing policies must be routinely monitored to help prevent excessive price erosion and ensure sustainable adoption. A heartfelt thanks to everyone who attended the presentation and shared their thoughts! If you weren't able to attend but want to connect to hear more, please do reach out to Vishal Yadav, Enzo Straccia, or Herve Lilliu! #Biosimilars #MarketAccess #PricingStrategies #ISPOR2024 #Inbeeo

🎤📋👥𝗜𝗻𝗯𝗲𝗲𝗼'𝘀 𝗽𝗿𝗲𝘀𝗲𝗻𝗰𝗲 𝗮𝘁 𝗜𝗦𝗣𝗢𝗥 𝟮𝟬𝟮𝟰!🎤📋👥 In case you did not get a chance to stop by our poster or missed our podium presentation at ISPOR, here is a summary of activities we participated at ISPOR 2024: Our Inbeeo experts were excited to present and discuss some key topics with attendees during the podium and poster presentations, including: 1.   Assessing the Impact of Access Policies on Biosimilar Pricing: A Comparative Study of Five Major European Markets 2.   Reimbursement Incentives for Antibiotics in Eleven European Countries: A Comparative Analysis ✨ Stay tuned for upcoming posts, where we will dive deeper into each of these topics! ✨ Feel free to reach out if you’d like to continue the conversation or have any questions. Thanks to everyone who joined us—we look forward to connecting with you again! #ISPOR #MarketAccess #Inbeeo #HealthEconomics #HTA #Pharma

🎯𝗜-𝗟𝗔𝗦 𝗥𝗲𝗰𝗮𝗽 #𝟯: 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗔𝗰𝗰𝗲𝘀𝘀 𝗶𝗻𝘁𝗼 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗠𝗮𝗸𝗶𝗻𝗴 🎯 At the Inbeeo Leaders in Access Summit 2024, we discussed the importance of integrating access into decision-making. It is widely accepted that Market Access has yet to realise its full potential impact across all clinical development stages, particularly in preclinical and phase 1 development. What are the biggest impediments to developing a truly successful market access strategy?   -   Continued perception of Market Access as a specialist function as opposed to a strategic partner  -   Market access is often not represented in key decision forums due to the lack of organisational influence networks   -   Lack of truly effective influence networks and challenge of the Market Access representative to be a ‘listened to’ voice in the room So, how do we think these challenges could be overcome? -   𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗲𝗱 𝗳𝗼𝗰𝘂𝘀 𝗼𝗻 𝗮𝗰𝗰𝗲𝘀𝘀 𝗲𝗱𝘂𝗰𝗮𝘁𝗶𝗼𝗻, for example by requiring Market Access training for progression into corporate leadership roles, which would increase the awareness of access as a strategic function -   𝗦𝗲𝗲𝗸𝗶𝗻𝗴 𝗼𝘂𝘁 𝗮𝗰𝗰𝗲𝘀𝘀 𝗰𝗵𝗮𝗺𝗽𝗶𝗼𝗻𝘀 𝗶𝗻 𝗖-𝘀𝘂𝗶𝘁𝗲, peripheral leadership and governance, hiring more corporate leaders with a background in Market Access would help develop a broader appreciation of the importance of true strategic planning and effective execution  -   𝗠𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗰𝗮𝘀𝗲 𝗳𝗼𝗿 𝗴𝗿𝗲𝗮𝘁𝗲𝗿 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗶𝗻 𝗮𝗰𝗰𝗲𝘀𝘀 by implementing early integrated value propositions, and providing clear impact scenarios Stay tuned for the final post from the Leaders in Access Summit on Corporate Social Responsibility in Access Strategy! Reach out to Enzo Straccia or Charlotte Langbo to learn more about our Inbeeo Leaders in Access events for 2025! #Pharmaceuticals #MarketAccess #ILAS #LeadersInAcccessSummit #AccessStrategy

💡 Is "Buy One, Give One" the future of pharmaceutical equity pricing? Marie-Stella-Maris (B Corp) uses this model to fund clean water initiatives. Could pharma adopt a similar approach to balance Global Pharmaceutical Pricing and #ESG objectives? In our latest blog, Christel Jansen explores how pharma companies can align commercial sustainability with equitable access, drawing lessons from outside the industry. 👉 Read more: https://lnkd.in/e7AAYbKX Are you aiming to align your Market Access and ESG goals while expanding global access? Let’s explore how to strategically balance commercial sustainability with equitable access in your market access initiatives. Feel free to connect to start the conversation! #lifesciences #pharmaceuticals #marketacces #patientaccess #globalhealth #accesstomedicines #drugpricing #equitypricing

That's a wrap from ISPOR 2024! 🎉 A fantastic few days for Team Inbeeo as part of the Enosium Life Science group. Wonderful to reconnect with colleagues and make plenty of new connections too! 𝗢𝘂𝗿 𝗸𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗰𝗼𝗻𝗴𝗿𝗲𝘀𝘀: 1. 𝗝𝗖𝗔 𝗶𝘀 𝗙𝗿𝗼𝗻𝘁 𝗮𝗻𝗱 𝗖𝗲𝗻𝘁𝗿𝗲: With less than 2 months until the JCA, it was a major focus. There's optimism that the JCA will promote transparency and elevate evidence standards across the industry 2. 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝘁𝗵𝗲 𝗡𝗮𝗺𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗚𝗮𝗺𝗲: There's a clear interest among countries to move towards enhanced cross-border collaboration beyond just HTA, extending into procurement and potentially even pricing! 3. 𝗙𝘂𝘁𝘂𝗿𝗲-𝗣𝗿𝗼𝗼𝗳𝗶𝗻𝗴 𝗶𝘀 𝗕𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗶𝗻𝗴𝗹𝘆 𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗳𝗼𝗿 𝗣𝗮𝘆𝗲𝗿𝘀: Payers are better equipped to control prices but recognize the need to future-proof through horizon scanning, safeguarding budgets, and improving management for upcoming challenges 4. 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗼𝗹𝗶𝗰𝗶𝗲𝘀 𝗳𝗼𝗿 𝗚𝗹𝗼𝗯𝗮𝗹 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗔𝗰𝗰𝗲𝘀𝘀: Ensuring access and affordability of medicines worldwide is gaining momentum. There's a growing need to enhance equity patient access even in regions where HTA frameworks don't currently exist. We are excited to further integrate these insights into our work at Inbeeo and continue contributing to helping you achieve your objectives. Please do contact us to discuss your needs further!

🌅𝗚𝗼𝗼𝗱 𝗺𝗼𝗿𝗻𝗶𝗻𝗴 𝗳𝗿𝗼𝗺 𝗯𝗲𝗮𝘂𝘁𝗶𝗳𝘂𝗹 𝗕𝗮𝗿𝗰𝗲𝗹𝗼𝗻𝗮! 🌅 Come and meet Inbeeo Consultant Tania Savant at ISPOR—The Professional Society for Health Economics and Outcomes Research this morning, where she will discuss Inbeeo's analysis of reimbursement incentives for antibiotics in Europe. 𝗦𝗲𝘀𝘀𝗶𝗼𝗻: Poster Session 3 📅 𝗗𝗮𝘁𝗲: Tuesday, 19 November 2024 ⏲𝗧𝗶𝗺𝗲: 10:30AM - 1:30PM Reach out to Tania Savant to hear more and arrange a coffee with the wider team! #ISPOR #Antibiotics #Policy #Europe #Reimbursement

🌅 𝗚𝗼𝗼𝗱 𝗺𝗼𝗿𝗻𝗶𝗻𝗴 𝗳𝗿𝗼𝗺 𝗯𝗲𝗮𝘂𝘁𝗶𝗳𝘂𝗹 𝗕𝗮𝗿𝗰𝗲𝗹𝗼𝗻𝗮!🌅 Don't miss Inbeeo Senior Consultant Vishal Yadav’s podium presentation today at ISPOR—The Professional Society for Health Economics and Outcomes Research, where he will discuss Inbeeo's analysis of the impact of access policies on biosimilar pricing in Europe. 𝗦𝗲𝘀𝘀𝗶𝗼𝗻: International Reference Pricing and Biosimilars: Theater 1, Poster and Exhibit Hall, 021, Level P0 📅 𝗗𝗮𝘁𝗲: Tuesday, 19 November 2024 ⏲𝗧𝗶𝗺𝗲: 1:45 Reach out to Vishal Yadav to hear more and arrange a coffee with the wider team! #ISPOR #marketaccess #Policy #Europe #ReimbursementandPricing

 🔏💡 𝗜-𝗟𝗔𝗦 𝗥𝗲𝗰𝗮𝗽 #𝟮: 𝗜𝗥𝗔 𝗜𝗺𝗽𝗮𝗰𝘁𝘀 𝗼𝗻 𝗔𝗰𝗰𝗲𝘀𝘀 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 🔏💡 The announcement of the initial ten IRA-negotiated drug prices sparked significant discussion back in August of this year, prompting a deeper conversation with leaders at the Inbeeo Leaders in Access 2024 Summit. With an upcoming fifty drugs to be selected and negotiated by 2030, including Part B drugs, the impact to the industry could be more significant than what we are seeing with the first ten selected, where estimated existing rebates render negotiated prices at somewhat marginal by way of impact. So what does it mean looking ahead? •   𝗜𝗺𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗹𝗮𝘂𝗻𝗰𝗵 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆 𝗮𝗿𝗲 𝗻𝗼𝘁 𝗶𝗺𝗺𝗶𝗻𝗲𝗻𝘁, however, there is increased pressure on the US-first strategy, given the now shorter time horizons to realize investment •   𝗕𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝘃𝗼𝗹𝘂𝗺𝗲 𝗲𝗹𝘀𝗲𝘄𝗵𝗲𝗿𝗲 is an open question, but not expected to be prioritized short-term •   𝗙𝘂𝘁𝘂𝗿𝗲 𝗿𝗼𝘂𝗻𝗱𝘀 𝗼𝗳 𝗻𝗲𝗴𝗼𝘁𝗶𝗮𝘁𝗶𝗼𝗻 are expected to ensue as planned, with the organization and precedence now established •   𝗖𝗹𝗮𝗿𝗶𝘁𝘆 𝗮𝗿𝗼𝘂𝗻𝗱 𝗱𝗿𝘂𝗴 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻 𝗰𝗿𝗶𝘁𝗲𝗿𝗶𝗮 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗻𝗲𝗴𝗼𝘁𝗶𝗮𝘁𝗶𝗼𝗻 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 (especially for Part B drugs) is in high demand to prepare for future rounds of negotiation. For now, the public awaits CMS’s explanation of the first ten negotiated prices with the public, expected to be shared in March 2025 •   𝗔𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗯𝗼𝗮𝗿𝗱, 𝗶𝘁 𝗶𝘀 𝗮𝗴𝗿𝗲𝗲𝗱 𝘁𝗵𝗮𝘁 𝗣𝗕𝗠𝘀 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝗶𝗻𝗴 𝗶𝘀 𝗼𝗳𝗳-𝗯𝗮𝗹𝗮𝗻𝗰𝗲 in the current system – increased accountability will be needed to translate the intended IRA savings to patients Stay tuned for the continuation of the 𝗜-𝗟𝗔𝗦 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗿𝗲𝗰𝗮𝗽 𝘀𝗲𝗿𝗶𝗲𝘀 𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗰𝗼𝗺𝗶𝗻𝗴 𝘄𝗲𝗲𝗸𝘀, and reach out to Enzo Straccia or Charlotte Langbo to learn more about our Inbeeo Leaders in Access events for 2025! #ILAS #LeadersInAcccessSummit #Policy #IRA #AccessStrategy